Participation of the elderly, women, and minorities in pivotal trials supporting 2011–2013 U.S. Food and Drug Administration approvals
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Pivotal trials, the clinical studies that inform U.S. Food and Drug Administration (FDA) approval decisions, provide the foundational evidence supporting the safety and efficacy of novel therapeutics. We determined the representation of the elderly, women, and patients from racial and ethnic minorities in pivotal trials and whether the FDA is making subgroup efficacy analyses among these subpopulations available to the public. METHODS: We conducted a cross-sectional study of novel therapeutics approved by the FDA between 2011 and 2013. Using publicly available FDA documents, we collected information on the demographic characteristics of pivotal trial participants (age ≥65 years, sex [male, female], race [white, black, Asian, other], and ethnicity [Hispanic, non-Hispanic]) and determined the availability of subgroup analyses by age, sex, race, and ethnicity. RESULTS: We identified 86 novel therapeutic that were approved by the FDA between 2011 and 2013 for 92 indications on the basis of 206 pivotal trials. The median age of pivotal trial patients was 53.1 years (interquartile range 40.6-60.6), and the mean proportion of patients ≥65 years of age was 28.9 % (95 % CI 23.5-34.4 %). Similar proportions of pivotal trial participants were male (mean 50.3 %, 95 % CI 45.3-55.2 %) and female (mean 49.7 %, 95 % CI 44.7-54.7 %). Most participants were white (mean 79.2 %, 95 % CI 75.9-82.6 %), while the mean proportion of black patients was 7.4 % (95 % CI 5.5-9.3 %), that of Asian patients was 7.4 % (95 % CI 5.2-9.7 %), and that of patients of other races was 5.9 % (95 % CI 4.4-7.5 %). Information about ethnicity was available for only 59.8 % of indications, and where such data were available, the mean proportion of Hispanic participants was 13.3 % (95 % CI 10.3-16.3 %). FDA reviewers performed and made available subgroup efficacy analyses by age, sex, and race for at least one of the pivotal trials used as the basis of approval for over 80 % of indications. CONCLUSIONS: Although women are equally represented in pivotal trials supporting recent novel therapeutic approvals by the FDA, elderly patients and those from racial and ethnic minorities are underrepresented. FDA reviewers generally perform subgroup efficacy analyses by age, sex, and race and make these subgroup analyses available to the public.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Participation in Cancer Clinical Trials: Race-, Sex-, and Age-Based Disparities
Murthy, V. H., Krumholz, H. M., & Gross, C. P. (2004) · JAMA · doi:10.1001/jama.291.22.2720 · Cited by 2,078
Self-citationRepresentation of the Elderly, Women, and Minorities in Heart Failure Clinical Trials
Heiat, A., Gross, C. P., & Krumholz, H. M. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.15.1682 · Cited by 723 · cited 1×
“This finding indicates that racial disparities in clinical research participation that have been noted in the 1990s and 2000s likely persist today [4, 5, 8].”
BackgroundSelf-citationRepresentation of Women in Randomized Clinical Trials of Cardiovascular Disease Prevention
Melloni, C., Berger, J. S., Wang, T. Y., Gunes, F., Stebbins, A., Pieper, K. S., Dolor, R. J., Douglas, P. S., Mark, D. B., & Newby, L. K. (2010) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.110.868307 · Cited by 455
Cited by
Lipid management in patients with chronic kidney disease
Ferro, C. J., Mark, P. B., Kanbay, M., Sarafidis, P., Heine, G. H., Rossignol, P., Massy, Z. A., Mallamaci, F., Valdivielso, J. M., Malyszko, J., et al. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0072-9 · Cited by 273
Emerging technologies and analytics for a new era of value-centered marketing in healthcare
Agarwal, R., Dugas, M., Gao, G. (., & Kannan, P. K. (2020) · Journal of the Academy of Marketing Science · doi:10.1007/s11747-019-00692-4 · Cited by 175
“For example, racial and ethnic minorities are generally underrepresented in clinical trials (Downing et al. 2016; Susukida et al. 2016), meaning analytic tools using clinical trial data for development are at considerable risk for bias.”
BackgroundUnderrepresentation of Hispanics and Other Minorities in Clinical Trials: Recruiters’ Perspectives
Occa, A., Morgan, S. E., & Potter, J. E. (2018) · Journal of Racial and Ethnic Health Disparities · doi:10.1007/s40615-017-0373-x · Cited by 78
McCoy, R. G., Herrin, J., Swarna, K. S., Deng, Y., Kent, D. M., Ross, J. S., Umpierrez, G. E., Galindo, R. J., Crown, W. H., Borah, B. J., et al. (2024) · Nature Cardiovascular Research · doi:10.1038/s44161-024-00453-9 · Cited by 30
Self-citation
Metadata
- Authors
- Downing, N. S., Shah, N. D., Neiman, J. H., Aminawung, J. A., Krumholz, H. M., & Ross, J. S.
- Venue
- Trials
- Published
- 2016-04-14
- Volume
- 17
- Issue
- 1
- Pages
- 199-199
- ISSN
- 1745-6215 (ISSN-L)
- OpenAlex
- W2340835891
- Cited by
- 83
- References
- 3
- FWCI
- 9.07
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Participation of the elderly, women, and minorities in pivotal trials supporting 2011–2013 U.S. Food and Drug Administration approvals. https://app.cochat.ai/papers/10.1186/s13063-016-1322-4
- The paper
- Downing, N. S., Shah, N. D., Neiman, J. H., Aminawung, J. A., Krumholz, H. M., & Ross, J. S. (2016). Participation of the elderly, women, and minorities in pivotal trials supporting 2011–2013 U.S. Food and Drug Administration approvals. Trials. https://doi.org/10.1186/s13063-016-1322-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.